Understanding Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, it is a cancer that starts in white blood cells called B-lymphocytes. These cells grow uncontrollably and can form lumps in lymph nodes or other organs such as the spleen or liver. DLBCL grows quickly but it is often treatable. Common symptoms include painless swelling of lymph nodes, fever, night sweats, fatigue, and weight loss. Diagnosis usually involves a biopsy, blood tests, and scans. Treatment often includes immunochemotherapy, and newer options, such as targeted therapies and CAR-T cell therapy may be available if the disease returns.
Below here from Corp
Confronting unmet medical needs in patients with cancer and solid tumors
Despite best efforts, there are still cancers that recur or that are refractory; that cause heavily treated patients to fail multiple lines of therapy; and that do not produce a durable and complete response. Following are the diseases that need new approaches to address unmet medical needs in cancer therapy.
Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL, the most common non-Hodgkin lymphoma (NHL), is an aggressive type of NHL that is curable with immunochemotherapy in 50% to 60% of cases.1 For the up to 40% of patients who fail 1L therapy, however, prognoses are poor, worsening with each line of therapy as the burden increases and chance for cure or long-term disease-free survival decreases.2,3
Alderuccio JP, et al. Lancet Haematology. Jan 2025
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
Epperla N, et al. Blood Cancer Journal. Nov 2024
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Follicular Lymphoma (FL)
Follicular lymphoma (FL) is typically a slow-growing or indolent form of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes, making it a B-cell lymphoma. This lymphoma subtype accounts for 20 to 30 percent of all NHL cases. (LRF reference) As the most prevalent indolent lymphoma and the second most common NHL, it has a relapsing and remitting course with the potential to progress to aggressive disease.9
Marginal Zone Lymphoma (MZL)
Marginal zone lymphomas (MZLs) are a group of slow-growing or indolent B-cell non-Hodgkin lymphomas (NHLs), that develop in a part of the lymph node that help the body fight tissue called the marginal zone. MZL is the third most common NHL and accounts for approximately 5 to 10% of all NHLs.10 MZL is a heterogenous disease with 3 subtypes (extranodal, nodal, and splenic). Each subtype has different symptoms, treatments, and prognoses.11
Selected Advanced Solid Tumors
There is an unmet medical need for patients with selected solid tumors that are locally advanced or metastatic and have failed or are intolerant to any established therapy.7
Explore our virtual congress experience
Access more resources at adctmedical.com
References
References: Lymphoma Research Foundation. Understanding Diffuse Large B-Cell Lymphoma (DLBCL). https://lymphoma.org/understanding-lymphoma/about-lymphoma/types/dlbcl